Great Hope for Retatrutide: Triple–Hormone-Receptor Agonist for Obesity

From Dr. Peter McCullough MD

By Peter A. McCullough, MD, MPH The first GLP-1 receptor agonist, exenatide (Byetta), was approved by the FDA in 2005 for the treatment of type 2 diabetes. Since that time there has been an explosion in numbers of products and expanding indications, particularly for the treatment of obesity. Here’s a more detailed timeline of GLP-1 […]

Mar 22nd 2025 5:05am EDT